SCHEMBL4889077

SCHEMBL4889077

NCCCCC(NC(=O)CNc1cccc(F)c1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 5/20 0.54
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GRK2 P25098 2/20 0.42
GRK3 P35626 2/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
SLC6A5 Q9Y345 1/20 0.42
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
C3AR1 Q16581 2/20 0.41
GRK5 P34947 1/20 0.40
SLC15A2 Q16348 1/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889060 1.00 FOLH1 (0.54) FOLH1CTSLCTSBCTSSCTSK
SCHEMBL4599332 0.87 FOLH1 (0.55) FOLH1MEN1KMT2AGRK2GRK3
SCHEMBL4599544 0.86 FOLH1 (0.49) FOLH1CA1CA2SLC6A5MMP2
SCHEMBL4599538 0.86 FOLH1 (0.49) FOLH1CA1CA2SLC6A5MMP2
SCHEMBL4889467 0.86 MEN1 (0.46) FOLH1MEN1KMT2AGRK2GRK3
SCHEMBL4889478 0.86 MEN1 (0.46) FOLH1MEN1KMT2AGRK2GRK3
SCHEMBL4889214 0.85 SMN1; SMN2 (0.51) MEN1KMT2AGRK2RAB9A
SCHEMBL4889227 0.85 SMN1; SMN2 (0.51) MEN1KMT2AGRK2RAB9A
SCHEMBL4600219 0.83 MTNR1A (0.47) MEN1KMT2AGRK2GRK3SLC6A5
SCHEMBL4739946 0.83 GRK2 (0.47) GRK2GRK3MMP2MMP9GRK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE MIGENIX INC. (CA) 2008-07-17 US disclosed
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF HAVCR2, ADAR, NSUN2 FOLH1 771/4885CTSL 922/4885CTSB 1465/4885
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE POLQ, POLI, POLH FOLH1 1486/4885CTSL 1829/4885CTSB 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.